133 related articles for article (PubMed ID: 28434764)
1. Novel non-trimethoxylphenyl piperlongumine derivatives selectively kill cancer cells.
Zhang Y; Ma H; Wu Y; Wu Z; Yao Z; Zhang W; Zhuang C; Miao Z
Bioorg Med Chem Lett; 2017 Jun; 27(11):2308-2312. PubMed ID: 28434764
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents.
Wu Y; Min X; Zhuang C; Li J; Yu Z; Dong G; Yao J; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Wei Y; Zhang H; Zhang W; Miao Z
Eur J Med Chem; 2014 Jul; 82():545-51. PubMed ID: 24937186
[TBL] [Abstract][Full Text] [Related]
3. Horner-Wadsworth-Emmons approach to piperlongumine analogues with potent anti-cancer activity.
Han LC; Stanley PA; Wood PJ; Sharma P; Kuruppu AI; Bradshaw TD; Moses JE
Org Biomol Chem; 2016 Aug; 14(31):7585-93. PubMed ID: 27443386
[TBL] [Abstract][Full Text] [Related]
4. Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation.
Liu JM; Pan F; Li L; Liu QR; Chen Y; Xiong XX; Cheng K; Yu SB; Shi Z; Yu AC; Chen XQ
Biochem Biophys Res Commun; 2013 Jul; 437(1):87-93. PubMed ID: 23796709
[TBL] [Abstract][Full Text] [Related]
5. Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation.
Liu X; Wang Y; Zhang X; Gao Z; Zhang S; Shi P; Zhang X; Song L; Hendrickson H; Zhou D; Zheng G
Bioorg Med Chem; 2018 Aug; 26(14):3925-3938. PubMed ID: 29925484
[TBL] [Abstract][Full Text] [Related]
6. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer.
Zou P; Xia Y; Ji J; Chen W; Zhang J; Chen X; Rajamanickam V; Chen G; Wang Z; Chen L; Wang Y; Yang S; Liang G
Cancer Lett; 2016 May; 375(1):114-126. PubMed ID: 26963494
[TBL] [Abstract][Full Text] [Related]
7. Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells.
Kim YH; Yoon YJ; Lee YJ; Kim CH; Lee S; Choung DH; Han DC; Kwon BM
Bioorg Med Chem Lett; 2018 Aug; 28(14):2566-2572. PubMed ID: 29807795
[TBL] [Abstract][Full Text] [Related]
8. Piperlongumine Suppresses Proliferation of Human Oral Squamous Cell Carcinoma through Cell Cycle Arrest, Apoptosis and Senescence.
Chen SY; Liu GH; Chao WY; Shi CS; Lin CY; Lim YP; Lu CH; Lai PY; Chen HR; Lee YR
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27120594
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel ROS inducer by merging the fragments of piperlongumine and dicoumarol.
Xu X; Fang X; Wang J; Zhu H
Bioorg Med Chem Lett; 2017 Mar; 27(5):1325-1328. PubMed ID: 28159415
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents.
Zou Y; Yan C; Zhang H; Xu J; Zhang D; Huang Z; Zhang Y
Eur J Med Chem; 2017 Sep; 138():313-319. PubMed ID: 28686911
[TBL] [Abstract][Full Text] [Related]
11. Piperlongumine and immune cytokine TRAIL synergize to promote tumor death.
Li J; Sharkey CC; King MR
Sci Rep; 2015 May; 5():9987. PubMed ID: 25984950
[TBL] [Abstract][Full Text] [Related]
12. Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization.
Liu D; Qiu XY; Wu X; Hu DX; Li CY; Yu SB; Pan F; Chen XQ
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):165-172. PubMed ID: 29037814
[TBL] [Abstract][Full Text] [Related]
13. Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivo.
Duan C; Zhang B; Deng C; Cao Y; Zhou F; Wu L; Chen M; Shen S; Xu G; Zhang S; Duan G; Yan H; Zou X
Tumour Biol; 2016 Aug; 37(8):10793-804. PubMed ID: 26874726
[TBL] [Abstract][Full Text] [Related]
14. Overview of piperlongumine analogues and their therapeutic potential.
Zhu P; Qian J; Xu Z; Meng C; Zhu W; Ran F; Zhang W; Zhang Y; Ling Y
Eur J Med Chem; 2021 Aug; 220():113471. PubMed ID: 33930801
[TBL] [Abstract][Full Text] [Related]
15. Piperlongumine (piplartine) as a lead compound for anticancer agents - Synthesis and properties of analogues: A mini-review.
Piska K; Gunia-Krzyżak A; Koczurkiewicz P; Wójcik-Pszczoła K; Pękala E
Eur J Med Chem; 2018 Aug; 156():13-20. PubMed ID: 30006159
[TBL] [Abstract][Full Text] [Related]
16. Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.
Xiong XX; Liu JM; Qiu XY; Pan F; Yu SB; Chen XQ
Acta Pharmacol Sin; 2015 Mar; 36(3):362-74. PubMed ID: 25619389
[TBL] [Abstract][Full Text] [Related]
17. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells.
Gong LH; Chen XX; Wang H; Jiang QW; Pan SS; Qiu JG; Mei XL; Xue YQ; Qin WM; Zheng FY; Shi Z; Yan XJ
Oxid Med Cell Longev; 2014; 2014():906804. PubMed ID: 24895529
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
Punganuru SR; Madala HR; Venugopal SN; Samala R; Mikelis C; Srivenugopal KS
Eur J Med Chem; 2016 Jan; 107():233-44. PubMed ID: 26599530
[TBL] [Abstract][Full Text] [Related]
19. Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems.
Wang H; Jiang H; Corbet C; de Mey S; Law K; Gevaert T; Feron O; De Ridder M
Cancer Lett; 2019 May; 450():42-52. PubMed ID: 30790679
[TBL] [Abstract][Full Text] [Related]
20. Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation.
Yan WJ; Wang Q; Yuan CH; Wang F; Ji Y; Dai F; Jin XL; Zhou B
Free Radic Biol Med; 2016 Aug; 97():109-123. PubMed ID: 27233942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
